Use of plasma B-type natriuretic peptide level to identify asymptomatic hypertensive patients with abnormal diurnal blood pressure variation profiles: Nondippers, extreme dippers, and risers

Hypertension Research

Volumn 30, Issue 7, 2007, Pages 651-658

  Nakatsu, Takaaki ^a   Shinohata, Ryoko ^b   Mashima, Keiichi ^a   Yuki, Yoko ^a   Nishitani, Aya ^a   Toyonaga, Shinji ^a   Ogawa, Hiroko ^b   Hirohata, Satoshi ^b   Usui, Shinichi ^b   Kusachi, Shozo ^b  

^a Kagawaken Saiseikai Hospital   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Ambulatory blood pressure monitoring; Clinical study; Essential hypertension; Immunoassay; Peptide

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ALGORITHM; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME IMMUNOASSAY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; SENSITIVITY AND SPECIFICITY;

EID: 34548050719     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.651     Document Type: Article

References (41)

1. Hirotsu C, Ohta E, Hirose N, Shimizu K: Profile analysis of 24-hours measurements of blood pressure. Biometrics 2003; 59: 907-915.
2. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K: Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38: 852-857.
3. O'Brien E, Sheridan J, O'Malley K: Dippers and non-dippers. Lancet 1988; 2: 397.
4. Ohkubo T, Imai Y, Tsuji I, et al: Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens 1997; 10: 1201-1207.
5. Shimada K, Kawamoto A, Matsubayashi K, Nishinaga M, Kimura S, Ozawa T: Diurnal blood pressure variations and silent eerebrovascular damage in elderly patients with hypertension. J Hypertens 1992; 10: 875-878.
6. Verdecchia P, Schillaci G, Borgioni C, et al: Altered circathan blood pressure profile and prognosis. Blood Press Monit 1997; 2: 347-352.
7. Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K: Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130-135.
8. Imai Y: Prognostic significance of ambulatory blood pressure. Blood Press Monit 1999; 4: 249-256.
9. Yasue H, Yoshimura M, Sumida H, et al: Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
10. Ogawa Y, Nakao K, Mukoyama M, et al: Rat brain natriuretic peptide - tissue distribution and molecular form. Endocrinology 1990; 126: 2225-2227.
11. Ogawa Y, Nakao K, Mukoyama M, et al: Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res 1991; 69: 491-500.
12. Hosoda K, Nakao K, Mukoyama M, et al: Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension 1991; 17: 1152-1155.
13. Mukoyama M, Nakao K, Hosoda K, et al: Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412.
14. Omland T, Aakvaag A, Vik-Mo H: Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996; 76: 232-237.
15. Rodeheffer RJ: Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol 2004; 44: 740-749.
16. Tsutamoto T, Wada A, Maeda K, et al: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasnia brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
17. Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K: Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002; 25: 669-676.
18. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M: Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem 2005; 51: 2245-2251.
19. Conen D, Zeller A, Pfisterer M, Martina B: Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol 2006;
20. Wofford MR, King DS, Wyatt SB, Jones DW: Secondary hypertension: detection and management for the primary care provider. J Clin Hypertens (Greenwich) 2000; 2: 124-131.
21. Rossi GP, Seccia TM, Pessina AC: Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci 2007; 44: 1-85.
22. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043-3045.
23. Kono M, Yamauchi A, Tsuji T: An immunoradiometric assay for brain natriuretic peptide in human plasam. Jpn Soc Nucl Med Technol 1993; 13: 2-7.
24. Ono H, Morita J, Morita K: Evaluation of BNP and troponin T measuring reagents using the full-auto micro plate chemiluminescence analyzer AP-96c. J Anal Bio-Sci 2004; 27: 335-342 (in Japanese).
25. Knudsen CW, Omland T, Clopton P, et al: Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol 2005; 46: 838-844.
26. Clerico A, Emdin M: Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50: 33-50.
27. Furst H, Hard WH, Haberl R, et al: Silent cerebral infarction: risk factor for stroke complicating carotid endarterectomy. World J Surg 2001; 25: 969-974.
28. Ezekowitz MD, James KE, Nazarian SM, et al, The Veterans Affairs Stroke Prevention in Nonrheurnatie Atrial Fibrillation Investigators: Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. Circulation 1995; 92: 2178-2182.
29. Mallion JM, Baguet JP, Siche JP, Tremel F, De Gaudemaris R: Clinical value of ambulatory blood pressure monitoring. J Hypertens 1999; 17: 585-595.
30. Timio M, Venanzi S, Lolli S, et al: "Non-dipper" hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol 1995; 43: 382-387.
31. Maisel A: B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med 2002; 3 (Suppl 4): S10-S17.
32. McCullough PA, Nowak RM, McCord J, et al: B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416-422.
33. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M, Giannessi D: The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 2002; 40: 371-377.
34. Sherwood A, Steffen PR, Blumenthal JA, Kuhn C, Hinderliter AL: Nighttime blood pressure dipping: the role of the sympathetic nervous system. Am J Hypertens 2002; 15: 111-118.
35. Arita M, Minami E, Nakamura C, Ueno Y, Nishio I, Masuyama Y: Role of the sympathetic nervous system in the nocturnal fall in blood pressure. Hypertens Res 1996; 5: 195-200.
36. Takakuwa H, Ise T, Kato T, et al: Diurnal variation of hemodynamic indices in non-dipper hypertensive patients. Hypertens Res 2001; 24: 195-201.
37. Rizzoni D, Muiesan ML, Montani G, Zulli R, Calebich S, Agabiti-Rosei E: Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring. Am J Hypertens 1992; 5: 180-186.
38. Verdecchia P, Schillaci G, Guerrieri M, et al: Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-536.
39. Feola M, Boffano GM, Procopio M, Reynaud S, Allemano P, Rizzi G: Ambulatory 24-hour blood pressure monitoring: correlation between blood pressure variability and left ventricular hypertrophy in untreated hypertensive patients. G Ital Cardiol 1998; 28: 38-44.
40. Cuspidi C, Michev I, Meani S, et al: Reduced nocturnal fall in blood pressure, assessed by two ambulatory blood pressure monitorings and cardiac alterations in early phases of untreated essential hypertension. J Hum Hypertens 2003; 17: 245-251.
41. Della Mea P, Lupia M, Bandolin V, et al: Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens 2005; 18: 30-35.